Life Science Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Life Science Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AVANIR Pharmaceuticals
Zenvia Phase III PBA Trial Completes Patient Enrollment
March 31st, 2009
AVANIR Pharmaceuticals (NASDAQ: AVNR) announced that it has completed targeted enrollment of patients into the STAR trial, a confirmatory Phase III trial of Zenvia™ (dextromethorphan/quinidine [DM/Q]) in patients exhibiting signs and symptoms of pseudobulbar affect (PBA). The randomized, multi-center, international STAR trial is designed to compare the effects of Zenvia 30/10 mg, Zenvia 20/10 mg and placebo on involuntary crying/laughing episodes rates. “The completion of patient enrollment into the STAR trial is an important clinical milestone for Avanir,” said Dr. Randall Kaye, Avanir’s Chief Medical Officer. “We look forward to unblinding the data in the third...
Source: Life Science Weekly (2009-03-31)
|
